CN102459628A - 抗人cd52 免疫球蛋白 - Google Patents

抗人cd52 免疫球蛋白 Download PDF

Info

Publication number
CN102459628A
CN102459628A CN2010800312662A CN201080031266A CN102459628A CN 102459628 A CN102459628 A CN 102459628A CN 2010800312662 A CN2010800312662 A CN 2010800312662A CN 201080031266 A CN201080031266 A CN 201080031266A CN 102459628 A CN102459628 A CN 102459628A
Authority
CN
China
Prior art keywords
seq
antibody
nos
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800312662A
Other languages
English (en)
Chinese (zh)
Inventor
B.L.罗伯茨
S.尚卡拉
W.H.布龙迪克
W.M.西德尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102459628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Priority to CN201910228216.6A priority Critical patent/CN110016081A/zh
Priority to CN201410379748.7A priority patent/CN104231084B/zh
Publication of CN102459628A publication Critical patent/CN102459628A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
CN2010800312662A 2009-05-13 2010-05-13 抗人cd52 免疫球蛋白 Pending CN102459628A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201910228216.6A CN110016081A (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白
CN201410379748.7A CN104231084B (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17783709P 2009-05-13 2009-05-13
US61/177,837 2009-05-13
PCT/US2010/034704 WO2010132659A2 (en) 2009-05-13 2010-05-13 Anti-human cd52 immunoglobulins

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201410379748.7A Division CN104231084B (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白
CN201910228216.6A Division CN110016081A (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白

Publications (1)

Publication Number Publication Date
CN102459628A true CN102459628A (zh) 2012-05-16

Family

ID=43085579

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2010800312662A Pending CN102459628A (zh) 2009-05-13 2010-05-13 抗人cd52 免疫球蛋白
CN201910228216.6A Pending CN110016081A (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白
CN201410379748.7A Active CN104231084B (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201910228216.6A Pending CN110016081A (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白
CN201410379748.7A Active CN104231084B (zh) 2009-05-13 2010-05-13 抗人cd52免疫球蛋白

Country Status (19)

Country Link
US (5) US8617554B2 (cg-RX-API-DMAC7.html)
EP (3) EP3683317A3 (cg-RX-API-DMAC7.html)
JP (4) JP5894912B2 (cg-RX-API-DMAC7.html)
KR (5) KR20170113704A (cg-RX-API-DMAC7.html)
CN (3) CN102459628A (cg-RX-API-DMAC7.html)
AR (1) AR076770A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010249003B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1013085A2 (cg-RX-API-DMAC7.html)
CA (2) CA2939492C (cg-RX-API-DMAC7.html)
HK (2) HK1222682A1 (cg-RX-API-DMAC7.html)
IL (2) IL216141B (cg-RX-API-DMAC7.html)
MX (1) MX2011012047A (cg-RX-API-DMAC7.html)
MY (1) MY160126A (cg-RX-API-DMAC7.html)
NZ (2) NZ621170A (cg-RX-API-DMAC7.html)
RU (2) RU2016142225A (cg-RX-API-DMAC7.html)
SG (2) SG176060A1 (cg-RX-API-DMAC7.html)
TW (3) TWI529247B (cg-RX-API-DMAC7.html)
WO (1) WO2010132659A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201108077B (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644923B (zh) * 2013-03-15 2018-12-21 健臻公司 抗ｃｄ５２之抗體
CN109929835A (zh) * 2019-03-27 2019-06-25 中国人民解放军第四军医大学 一种鼠单克隆抗体功能轻链可变区基因的扩增方法
CN114502596A (zh) * 2019-07-02 2022-05-13 泰利克斯国际有限公司 对新生儿Fc受体具有减少的亲和力的针对CAIX的抗体

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2722184A1 (en) 2008-04-25 2009-10-29 Duke University Regulatory b cells and their uses
SG176060A1 (en) * 2009-05-13 2011-12-29 Genzyme Corp Anti-human cd52 immunoglobulins
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
US9814740B2 (en) * 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
WO2012144208A1 (ja) 2011-04-18 2012-10-26 国立大学法人東京大学 抗itm2a抗体を用いる癌の診断および治療
GB201109238D0 (en) * 2011-06-01 2011-07-13 Antitope Ltd Antibodies
CN109022465B (zh) 2011-10-28 2022-04-29 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
WO2013185165A1 (en) * 2012-06-14 2013-12-19 The Walter And Eliza Hall Institute Of Medical Research Cd-52 antibodies and their use in determining and enhancing an immune response in a subject
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
US20150299315A1 (en) * 2012-10-22 2015-10-22 Becton, Dickinson And Company Non-b-lineage cells capable of producing antibody
EP2970496B1 (en) 2013-03-12 2018-07-18 Institute of Arthritis Research LLC Immunologically active polypeptide
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
KR102042174B1 (ko) 2013-03-29 2019-11-08 삼성전자주식회사 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR102060540B1 (ko) * 2013-04-03 2019-12-31 삼성전자주식회사 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물
JP6433085B2 (ja) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド がんの処置に使用するための２−アセチルナフト［２，３−ｂ］フラン−４，９−ジオン
KR102186363B1 (ko) * 2013-09-06 2020-12-04 삼성전자주식회사 c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물
KR102192591B1 (ko) * 2013-09-09 2020-12-18 삼성전자주식회사 c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물
BR112017026025A2 (pt) 2015-06-03 2018-08-14 Boston Biomedical Inc composições que compreendem um inibidor de stemness de câncer e um agente imunoterápico para uso no tratamento de câncer
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
BR112018072394A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem a tau
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3554515A4 (en) 2016-12-15 2020-08-26 Duke University B10 REGULATORY CELL DEPLETION ANTIBODIES AND METHODS AND THEIR USE IN COMBINATION WITH IMMUNITY CHECKPOINT INHIBITORS
CN110546167A (zh) 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
JP2021511068A (ja) * 2017-12-20 2021-05-06 ラディミューン セラピュティックス， インク．Ｒａｄｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｅｎｔｒｉｎ−１に対する抗体、作製方法、及びその使用
CN113544148B (zh) 2018-12-19 2024-04-05 胡默波斯生物医学公司 中和乙型肝炎病毒的抗体和其用途
HRP20231338T1 (hr) 2018-12-20 2024-02-16 Vir Biotechnology, Inc. Kombinirana terapija hbv
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
TWI800824B (zh) * 2020-05-08 2023-05-01 大陸商亘喜生物科技（上海）有限公司 一種抗cd19抗體的抗體及其製備和應用
IL302786A (en) * 2020-11-19 2023-07-01 Genzyme Corp Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2025031965A1 (en) * 2023-08-04 2025-02-13 Cimeio Therapeutics Ag Discernible cell surface protein variants of cd52 for use in cell therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0616537B1 (en) * 1991-12-04 1999-03-03 British Technology Group Limited CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS
US20060204496A1 (en) * 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
US20070178098A1 (en) * 2005-12-30 2007-08-02 Merck Patent Gmbh Interleukin-6 antagonists
CN101052653A (zh) * 2004-09-02 2007-10-10 健泰科生物技术公司 抗FcγRⅡB受体抗体及其用途

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JPH0684377B2 (ja) 1986-04-17 1994-10-26 協和醗酵工業株式会社 新規化合物ｄｃ―８８ａ及びｄｃ―８９ａ１
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
DE68909441T2 (de) 1988-02-12 1994-02-10 British Tech Group Modifizierte Antikörper.
JP2598116B2 (ja) 1988-12-28 1997-04-09 協和醗酵工業株式会社 新規物質ｄｃ１１３
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5187186A (en) 1989-07-03 1993-02-16 Kyowa Hakko Kogyo Co., Ltd. Pyrroloindole derivatives
JP2510335B2 (ja) 1989-07-03 1996-06-26 協和醗酵工業株式会社 Ｄｃ―８８ａ誘導体
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9022547D0 (en) 1990-10-17 1990-11-28 Wellcome Found Purified immunoglobulin
GB9108056D0 (en) * 1991-04-16 1991-06-05 Hale Geoffrey Synthetic antigen
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5269388A (en) 1991-11-12 1993-12-14 Stress-Tek, Inc. Weighing bed
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US7119248B1 (en) 1994-04-12 2006-10-10 Miltenyi Biotec Gmbh Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
PT705833E (pt) 1994-04-22 2004-11-30 Kyowa Hakko Kogyo Kk Derivado de dc-89
US5550246A (en) 1994-09-07 1996-08-27 The Scripps Research Institute Calicheamicin mimics
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
CA2290485C (en) 1997-05-21 2008-08-05 Biovation Limited Method for the production of non-immunogenic proteins
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
ATE349438T1 (de) 1999-11-24 2007-01-15 Immunogen Inc Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung
AU778392B2 (en) 2000-03-03 2004-12-02 Cambridge Antibody Technology Limited Human antibodies against eotaxin and their use
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
US20020132983A1 (en) 2000-11-30 2002-09-19 Junghans Richard P. Antibodies as chimeric effector cell receptors against tumor antigens
JP2005512044A (ja) 2001-12-03 2005-04-28 アブジェニックス・インコーポレーテッド 結合特性に基づく抗体分類
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20050191632A1 (en) 2002-11-01 2005-09-01 John Byrd Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia
CN1225480C (zh) * 2002-12-18 2005-11-02 马菁 抗cd52单克隆抗体、其编码序列及应用
US7534427B2 (en) 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
AU2004226492A1 (en) * 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor
JP4644663B2 (ja) 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド ペプチド開裂部位を用いた単一ベクターからの組換えポリペプチドの高められた発現のための構成と方法
ES2384105T3 (es) 2003-11-01 2012-06-29 Merck Patent Gmbh Anticuerpo anti-CD52 modificado
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7655229B2 (en) 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
RU2007147414A (ru) * 2005-05-24 2009-07-10 Эйвестаджен Лимитед,In (In) Способ рекомбинантного получения моноклонального антитела к cd52, предназначенного для лечения хронического лимфолейкоза
NZ583636A (en) 2005-05-27 2011-12-22 Biogen Idec Inc Tweak binding antibodies
CA2649440A1 (en) * 2006-04-12 2007-10-25 Genzyme Corporation Methods of treating autoimmune diseases
EP2433649A3 (en) 2006-09-13 2012-10-31 Alcafleu Management GmbH & Co. KG Treatment of multiple sclerosis (MS) with campath-1H
EP2417974A1 (en) 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
JP2010530857A (ja) * 2007-06-22 2010-09-16 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 神経系障害、特に感染性海綿状脳症及びアルツハイマー病を治療するためのｃｄ５２抗原に対する抗体の使用
SG176060A1 (en) 2009-05-13 2011-12-29 Genzyme Corp Anti-human cd52 immunoglobulins
AU2010248935B2 (en) 2009-05-13 2016-12-15 Genzyme Corporation Methods and compositions for treating lupus
US20120058082A1 (en) 2009-05-13 2012-03-08 Genzyme Corporation Methods and compositions for treatment
SG10201704269RA (en) 2009-07-15 2017-06-29 Aimm Therapeutics Bv Gram-positive bacteria specific binding compounds
AU2011279073B2 (en) 2010-07-16 2016-06-09 Adimab, Llc Antibody libraries
ITMI20110376A1 (it) 2011-03-10 2012-09-11 Wilic Sarl Aerogeneratore raffreddato a fluido
GB201109238D0 (en) 2011-06-01 2011-07-13 Antitope Ltd Antibodies
AR095199A1 (es) 2013-03-15 2015-09-30 Genzyme Corp Anticuerpos anti-cd52
PL3204425T3 (pl) 2014-10-09 2021-03-08 Genzyme Corporation Glikomodyfikowane koniugaty przeciwciał z lekami
CN110546167A (zh) 2017-04-21 2019-12-06 建新公司 以抗-cd52抗体治疗多发性硬化症

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0616537B1 (en) * 1991-12-04 1999-03-03 British Technology Group Limited CDw52-SPECIFIC ANTIBODY FOR TREATMENT OF MULTIPLE SCLEROSIS
US20060204496A1 (en) * 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
CN101052653A (zh) * 2004-09-02 2007-10-10 健泰科生物技术公司 抗FcγRⅡB受体抗体及其用途
US20070178098A1 (en) * 2005-12-30 2007-08-02 Merck Patent Gmbh Interleukin-6 antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HEATHER L PULASKI, ET AL.: "Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer", 《JOURNAL OF TRANSLATIONAL MEDICINE》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI644923B (zh) * 2013-03-15 2018-12-21 健臻公司 抗ｃｄ５２之抗體
CN109929835A (zh) * 2019-03-27 2019-06-25 中国人民解放军第四军医大学 一种鼠单克隆抗体功能轻链可变区基因的扩增方法
CN114502596A (zh) * 2019-07-02 2022-05-13 泰利克斯国际有限公司 对新生儿Fc受体具有减少的亲和力的针对CAIX的抗体

Also Published As

Publication number Publication date
EP3683317A3 (en) 2020-09-30
TW201825115A (zh) 2018-07-16
KR20120111932A (ko) 2012-10-11
IL262639A (en) 2018-12-31
US20200040091A1 (en) 2020-02-06
EP3683317A2 (en) 2020-07-22
RU2603743C2 (ru) 2016-11-27
CN104231084A (zh) 2014-12-24
JP5894912B2 (ja) 2016-03-30
KR101537840B1 (ko) 2015-07-22
SG10201608169QA (en) 2016-11-29
KR20160103160A (ko) 2016-08-31
RU2016142225A (ru) 2018-12-18
US20220010024A1 (en) 2022-01-13
EP2429582A4 (en) 2013-01-23
KR20160005143A (ko) 2016-01-13
KR20170113704A (ko) 2017-10-12
US20160208010A1 (en) 2016-07-21
KR20140102764A (ko) 2014-08-22
SG176060A1 (en) 2011-12-29
US20120100152A1 (en) 2012-04-26
CA2939492C (en) 2019-03-19
TW201043694A (en) 2010-12-16
MY160126A (en) 2017-02-28
IL216141A0 (en) 2012-01-31
JP2016093194A (ja) 2016-05-26
CA2939492A1 (en) 2010-11-18
ZA201108077B (en) 2013-01-30
TWI614267B (zh) 2018-02-11
WO2010132659A2 (en) 2010-11-18
CN104231084B (zh) 2019-04-23
IL216141B (en) 2018-11-29
EP2998405A1 (en) 2016-03-23
MX2011012047A (es) 2011-12-14
US8617554B2 (en) 2013-12-31
HK1205152A1 (en) 2015-12-11
WO2010132659A3 (en) 2011-01-06
AR076770A1 (es) 2011-07-06
RU2011150516A (ru) 2013-06-20
JP2012526558A (ja) 2012-11-01
CN110016081A (zh) 2019-07-16
AU2010249003B2 (en) 2015-08-20
US20140341910A1 (en) 2014-11-20
EP2998405B1 (en) 2019-12-11
NZ621170A (en) 2015-08-28
TWI529247B (zh) 2016-04-11
HK1222682A1 (en) 2017-07-07
JP2018029624A (ja) 2018-03-01
CA2761800C (en) 2016-09-27
NZ596384A (en) 2014-03-28
TW201636367A (zh) 2016-10-16
CA2761800A1 (en) 2010-11-18
JP2014195474A (ja) 2014-10-16
AU2010249003A1 (en) 2011-11-03
US11945874B2 (en) 2024-04-02
BRPI1013085A2 (pt) 2020-11-03
EP2429582A2 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
US11945874B2 (en) Anti-human CD52 immunoglobulins
EP2331579A2 (en) Monoclonal antibodies
AU2014233685B2 (en) Anti-CD52 antibodies
AU2017202364B2 (en) Anti-human CD52 immunoglobulins
HK40031934A (en) Anti-human cd52 immunoglobulins
OA17634A (en) Anti-CD52 antibodies.

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120516